- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Advancing Pediatric Atopic Dermatitis Care: Challenges, Innovations, and Future Directions : Episode 4
Opinion
Video
Key Considerations for Evaluating Ruxolitinib Cream as a Treatment for Young Children
Author(s):
Lisa Swanson, MD, FAAD, discusses how factors such as the safety profile, efficacy, age-appropriate dosing, and potential long-term effects of ruxolitinib cream would be crucial in determining its place in treatment for young children.
Video Player is loading.
This news content has been independently developed and is not endorsed by the American Academy of Dermatology.
Video content above is prompted by the following:
- When considering an emerging topical JAK inhibitor like ruxolitinib cream for young children, what factors would be most important to you in determining its place in treatment?
Related Videos
Balancing Effective AD Symptom Control with Long-Term Safety in New Therapies
Supporting Caregivers in Successful Long-Term Atopic Dermatitis Management: The Role of Dermatologists
Challenges and Emerging Solutions in Treatment for Age Groups: Addressing Disease Control, Safety, and Usability
Challenges and Unmet Needs in Treating Pediatric Atopic Dermatitis
Utilizing Gene Expression Profiling to Avoid Unnecessary Interventions in a 72-Year-Old Woman With Melanoma
Differentiating Between JAK Inhibitors in Clinical Practice
IL-17 Inhibitor Treatment Impact on Quality of Life in Psoriasis and Psoriatic Arthritis
Clinical Attributes of IL-17 Inhibitors in Psoriasis
Laboratory Monitoring with Oral JAK Inhibitors
Gene Expression Profiling and Other Molecular Tests Utilized for Melanoma and Squamous Cell Carcinoma
Related Content
